APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

NMDA Receptor Antagonist

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global NMDA Receptor Antagonist Industry Growth and Trends Forecast to 2032

Report ID 174017400129 December 2025102 pages

Choose your research edition.

Industry ResearchNMDA Receptor Antagonist Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal NMDA Receptor Antagonist Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal NMDA Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NMDA Receptor Antagonist Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal NMDA Receptor Antagonist Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global NMDA Receptor Antagonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for NMDA Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for NMDA Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NMDA Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of NMDA Receptor Antagonist include Algernon Pharmaceuticals, ATAI Life Sciences, Avanir Pharmaceuticals, Axsome Therapeutics, Bexson Biomedical, Cessatech, DemeRx, PharmaTher and Relmada Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global NMDA Receptor Antagonist market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The NMDA Receptor Antagonist market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global NMDA Receptor Antagonist market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to NMDA Receptor Antagonist.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global NMDA Receptor Antagonist market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

NMDA Receptor Antagonist Market by Company

Algernon Pharmaceuticals

ATAI Life Sciences

Avanir Pharmaceuticals

Axsome Therapeutics

Bexson Biomedical

Cessatech

DemeRx

PharmaTher

Relmada Therapeutics

Seelos Therapeutics

Small Pharma

UCB

NMDA Receptor Antagonist Segment by Type

Vaccine

Monoclonal Antibody

NMDA Receptor Antagonist Segment by Application

Parkinson's Disease

Alzheimer's Disease

Others

NMDA Receptor Antagonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NMDA Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NMDA Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NMDA Receptor Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of NMDA Receptor Antagonist manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of NMDA Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Vaccine Table 2. Major Company of Monoclonal Antibody Table 3. Global NMDA Receptor Antagonist Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global NMDA Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 5. Global NMDA Receptor Antagonist Sales Market Share in Volume by Type (2021-2026) Table 6. Global NMDA Receptor Antagonist Sales by Type (2021-2026) & (US$ Million) Table 7. Global NMDA Receptor Antagonist Sales Market Share in Value by Type (2021-2026) Table 8. Global NMDA Receptor Antagonist Price by Type (2021-2026) & (US$/Unit) Table 9. Global NMDA Receptor Antagonist Sales by Type (2027-2032) & (K Units) Table 10. Global NMDA Receptor Antagonist Sales Market Share in Volume by Type (2027-2032) Table 11. Global NMDA Receptor Antagonist Sales by Type (2027-2032) & (US$ Million) Table 12. Global NMDA Receptor Antagonist Sales Market Share in Value by Type (2027-2032) Table 13. Global NMDA Receptor Antagonist Price by Type (2027-2032) & (US$/Unit) Table 14. North America NMDA Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 15. North America NMDA Receptor Antagonist Sales by Type (2021-2026) & (US$ Million) Table 16. Europe NMDA Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 17. Europe NMDA Receptor Antagonist Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific NMDA Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific NMDA Receptor Antagonist Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America NMDA Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 21. Latin America NMDA Receptor Antagonist Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa NMDA Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa NMDA Receptor Antagonist Sales by Type (2021-2026) & (US$ Million) Table 24. NMDA Receptor Antagonist Industry Trends Table 25. NMDA Receptor Antagonist Industry Drivers Table 26. NMDA Receptor Antagonist Industry Opportunities and Challenges Table 27. NMDA Receptor Antagonist Industry Restraints Table 28. Global NMDA Receptor Antagonist Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global NMDA Receptor Antagonist Revenue Market Share by Company (2021-2026) Table 30. Global NMDA Receptor Antagonist Sales by Company (2021-2026) & (K Units) Table 31. Global NMDA Receptor Antagonist Sales Share by Company (2021-2026) Table 32. Global NMDA Receptor Antagonist Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global NMDA Receptor Antagonist Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global NMDA Receptor Antagonist Major Company Production Sites and Headquarters Table 35. Global NMDA Receptor Antagonist Company, Product Type & Application Table 36. Global NMDA Receptor Antagonist Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global NMDA Receptor Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global NMDA Receptor Antagonist Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global NMDA Receptor Antagonist Sales by Region (2021-2026) & (K Units) Table 41. Global NMDA Receptor Antagonist Sales Market Share in Volume by Region (2021-2026) Table 42. Global NMDA Receptor Antagonist Sales by Region (2021-2026) & (US$ Million) Table 43. Global NMDA Receptor Antagonist Sales Market Share in Value by Region (2021-2026) Table 44. Global NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global NMDA Receptor Antagonist Sales by Region (2027-2032) & (K Units) Table 46. Global NMDA Receptor Antagonist Sales Market Share in Volume by Region (2027-2032) Table 47. Global NMDA Receptor Antagonist Sales by Region (2027-2032) & (US$ Million) Table 48. Global NMDA Receptor Antagonist Sales Market Share in Value by Region (2027-2032) Table 49. Global NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global NMDA Receptor Antagonist Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global NMDA Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 52. Global NMDA Receptor Antagonist Sales Market Share in Volume by Application (2021-2026) Table 53. Global NMDA Receptor Antagonist Sales by Application (2021-2026) & (US$ Million) Table 54. Global NMDA Receptor Antagonist Sales Market Share in Value by Application (2021-2026) Table 55. Global NMDA Receptor Antagonist Price by Application (2021-2026) & (US$/Unit) Table 56. Global NMDA Receptor Antagonist Sales by Application (2027-2032) & (K Units) Table 57. Global NMDA Receptor Antagonist Sales Market Share in Volume by Application (2027-2032) Table 58. Global NMDA Receptor Antagonist Sales by Application (2027-2032) & (US$ Million) Table 59. Global NMDA Receptor Antagonist Sales Market Share in Value by Application (2027-2032) Table 60. Global NMDA Receptor Antagonist Price by Application (2027-2032) & (US$/Unit) Table 61. North America NMDA Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 62. North America NMDA Receptor Antagonist Sales by Application (2021-2026) & (US$ Million) Table 63. Europe NMDA Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 64. Europe NMDA Receptor Antagonist Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific NMDA Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific NMDA Receptor Antagonist Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America NMDA Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 68. Latin America NMDA Receptor Antagonist Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa NMDA Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa NMDA Receptor Antagonist Sales by Application (2021-2026) & (US$ Million) Table 71. Algernon Pharmaceuticals Company Information Table 72. Algernon Pharmaceuticals Business Overview Table 73. Algernon Pharmaceuticals NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Algernon Pharmaceuticals NMDA Receptor Antagonist Product Portfolio Table 75. Algernon Pharmaceuticals Recent Development Table 76. ATAI Life Sciences Company Information Table 77. ATAI Life Sciences Business Overview Table 78. ATAI Life Sciences NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. ATAI Life Sciences NMDA Receptor Antagonist Product Portfolio Table 80. ATAI Life Sciences Recent Development Table 81. Avanir Pharmaceuticals Company Information Table 82. Avanir Pharmaceuticals Business Overview Table 83. Avanir Pharmaceuticals NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Avanir Pharmaceuticals NMDA Receptor Antagonist Product Portfolio Table 85. Avanir Pharmaceuticals Recent Development Table 86. Axsome Therapeutics Company Information Table 87. Axsome Therapeutics Business Overview Table 88. Axsome Therapeutics NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Axsome Therapeutics NMDA Receptor Antagonist Product Portfolio Table 90. Axsome Therapeutics Recent Development Table 91. Bexson Biomedical Company Information Table 92. Bexson Biomedical Business Overview Table 93. Bexson Biomedical NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Bexson Biomedical NMDA Receptor Antagonist Product Portfolio Table 95. Bexson Biomedical Recent Development Table 96. Cessatech Company Information Table 97. Cessatech Business Overview Table 98. Cessatech NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Cessatech NMDA Receptor Antagonist Product Portfolio Table 100. Cessatech Recent Development Table 101. DemeRx Company Information Table 102. DemeRx Business Overview Table 103. DemeRx NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. DemeRx NMDA Receptor Antagonist Product Portfolio Table 105. DemeRx Recent Development Table 106. PharmaTher Company Information Table 107. PharmaTher Business Overview Table 108. PharmaTher NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. PharmaTher NMDA Receptor Antagonist Product Portfolio Table 110. PharmaTher Recent Development Table 111. Relmada Therapeutics Company Information Table 112. Relmada Therapeutics Business Overview Table 113. Relmada Therapeutics NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Relmada Therapeutics NMDA Receptor Antagonist Product Portfolio Table 115. Relmada Therapeutics Recent Development Table 116. Seelos Therapeutics Company Information Table 117. Seelos Therapeutics Business Overview Table 118. Seelos Therapeutics NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Seelos Therapeutics NMDA Receptor Antagonist Product Portfolio Table 120. Seelos Therapeutics Recent Development Table 121. Small Pharma Company Information Table 122. Small Pharma Business Overview Table 123. Small Pharma NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Small Pharma NMDA Receptor Antagonist Product Portfolio Table 125. Small Pharma Recent Development Table 126. UCB Company Information Table 127. UCB Business Overview Table 128. UCB NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. UCB NMDA Receptor Antagonist Product Portfolio Table 130. UCB Recent Development Table 131. North America NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. North America NMDA Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 133. North America NMDA Receptor Antagonist Sales Market Share by Country (2021-2026) Table 134. North America NMDA Receptor Antagonist Sales Forecast by Country (2027-2032) & (K Units) Table 135. North America NMDA Receptor Antagonist Sales Market Share Forecast by Country (2027-2032) Table 136. North America NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. North America NMDA Receptor Antagonist Market Size by Country (2021-2026) & (US$ Million) Table 138. North America NMDA Receptor Antagonist Market Share by Country (2021-2026) Table 139. North America NMDA Receptor Antagonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. North America NMDA Receptor Antagonist Market Share Forecast by Country (2027-2032) Table 141. Europe NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Europe NMDA Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 143. Europe NMDA Receptor Antagonist Sales Market Share by Country (2021-2026) Table 144. Europe NMDA Receptor Antagonist Sales Forecast by Country (2027-2032) & (K Units) Table 145. Europe NMDA Receptor Antagonist Sales Market Share Forecast by Country (2027-2032) Table 146. Europe NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Europe NMDA Receptor Antagonist Market Size by Country (2021-2026) & (US$ Million) Table 148. Europe NMDA Receptor Antagonist Market Share by Country (2021-2026) Table 149. Europe NMDA Receptor Antagonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Europe NMDA Receptor Antagonist Market Share Forecast by Country (2027-2032) Table 151. Asia-Pacific NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Asia-Pacific NMDA Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 153. Asia-Pacific NMDA Receptor Antagonist Sales Market Share by Country (2021-2026) Table 154. Asia-Pacific NMDA Receptor Antagonist Sales Forecast by Country (2027-2032) & (K Units) Table 155. Asia-Pacific NMDA Receptor Antagonist Sales Market Share Forecast by Country (2027-2032) Table 156. Asia-Pacific NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Asia-Pacific NMDA Receptor Antagonist Market Size by Country (2021-2026) & (US$ Million) Table 158. Asia-Pacific NMDA Receptor Antagonist Market Share by Country (2021-2026) Table 159. Asia-Pacific NMDA Receptor Antagonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Asia-Pacific NMDA Receptor Antagonist Market Share Forecast by Country (2027-2032) Table 161. Latin America NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Latin America NMDA Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 163. Latin America NMDA Receptor Antagonist Sales Market Share by Country (2021-2026) Table 164. Latin America NMDA Receptor Antagonist Sales Forecast by Country (2027-2032) & (K Units) Table 165. Latin America NMDA Receptor Antagonist Sales Market Share Forecast by Country (2027-2032) Table 166. Latin America NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Latin America NMDA Receptor Antagonist Market Size by Country (2021-2026) & (US$ Million) Table 168. Latin America NMDA Receptor Antagonist Market Share by Country (2021-2026) Table 169. Latin America NMDA Receptor Antagonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Latin America NMDA Receptor Antagonist Market Share Forecast by Country (2027-2032) Table 171. Middle East and Africa NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 172. Middle East and Africa NMDA Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 173. Middle East and Africa NMDA Receptor Antagonist Sales Market Share by Country (2021-2026) Table 174. Middle East and Africa NMDA Receptor Antagonist Sales Forecast by Country (2027-2032) & (K Units) Table 175. Middle East and Africa NMDA Receptor Antagonist Sales Market Share Forecast by Country (2027-2032) Table 176. Middle East and Africa NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Middle East and Africa NMDA Receptor Antagonist Market Size by Country (2021-2026) & (US$ Million) Table 178. Middle East and Africa NMDA Receptor Antagonist Market Share by Country (2021-2026) Table 179. Middle East and Africa NMDA Receptor Antagonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Middle East and Africa NMDA Receptor Antagonist Market Share Forecast by Country (2027-2032) Table 181. Key Raw Materials Table 182. Raw Materials Key Suppliers Table 183. NMDA Receptor Antagonist Distributors List Table 184. NMDA Receptor Antagonist Customers List Table 185. Research Programs/Design for This Report Table 186. Authors List of This Report Table 187. Secondary Sources Table 188. Primary Sources List of Figures Figure 1. NMDA Receptor Antagonist Image Figure 2. Global NMDA Receptor Antagonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NMDA Receptor Antagonist Market Size (2021-2032) & (US$ Million) Figure 4. Global NMDA Receptor Antagonist Sales (2021-2032) & (K Units) Figure 5. Vaccine Image Figure 6. Global Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 7. Monoclonal Antibody Image Figure 8. Global Monoclonal Antibody Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global NMDA Receptor Antagonist Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global NMDA Receptor Antagonist Market Share by Type 2025 VS 2032 Figure 11. North America NMDA Receptor Antagonist Sales Market Share in Volume by Type in 2025 Figure 12. North America NMDA Receptor Antagonist Sales Market Share in Value by Type in 2025 Figure 13. Europe NMDA Receptor Antagonist Sales Market Share in Volume by Type in 2025 Figure 14. Europe NMDA Receptor Antagonist Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific NMDA Receptor Antagonist Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific NMDA Receptor Antagonist Sales Market Share in Value by Type in 2025 Figure 17. Latin America NMDA Receptor Antagonist Sales Market Share in Volume by Type in 2025 Figure 18. Latin America NMDA Receptor Antagonist Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa NMDA Receptor Antagonist Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa NMDA Receptor Antagonist Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 NMDA Receptor Antagonist Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Parkinson's Disease Image Figure 24. Global Parkinson's Disease Sales YoY Growth (2021-2032) & (K Units) Figure 25. Alzheimer's Disease Image Figure 26. Global Alzheimer's Disease Sales YoY Growth (2021-2032) & (K Units) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global NMDA Receptor Antagonist Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global NMDA Receptor Antagonist Market Share by Application 2025 VS 2032 Figure 31. North America NMDA Receptor Antagonist Sales Market Share in Volume by Application in 2025 Figure 32. North America NMDA Receptor Antagonist Sales Market Share in Value by Application in 2025 Figure 33. Europe NMDA Receptor Antagonist Sales Market Share in Volume by Application in 2025 Figure 34. Europe NMDA Receptor Antagonist Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific NMDA Receptor Antagonist Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific NMDA Receptor Antagonist Sales Market Share in Value by Application in 2025 Figure 37. Latin America NMDA Receptor Antagonist Sales Market Share in Volume by Application in 2025 Figure 38. Latin America NMDA Receptor Antagonist Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa NMDA Receptor Antagonist Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa NMDA Receptor Antagonist Sales Market Share in Value by Application in 2025 Figure 41. North America NMDA Receptor Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America NMDA Receptor Antagonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America NMDA Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America NMDA Receptor Antagonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe NMDA Receptor Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe NMDA Receptor Antagonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe NMDA Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe NMDA Receptor Antagonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific NMDA Receptor Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific NMDA Receptor Antagonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific NMDA Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific NMDA Receptor Antagonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America NMDA Receptor Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America NMDA Receptor Antagonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America NMDA Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America NMDA Receptor Antagonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa NMDA Receptor Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa NMDA Receptor Antagonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa NMDA Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa NMDA Receptor Antagonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. NMDA Receptor Antagonist Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. NMDA Receptor Antagonist Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccine
  • Monoclonal Antibody
Applications
  • Parkinson's Disease
  • Alzheimer's Disease
  • Others
Companies covered
  • Algernon Pharmaceuticals
  • ATAI Life Sciences
  • Avanir Pharmaceuticals
  • Axsome Therapeutics
  • Bexson Biomedical
  • Cessatech
  • DemeRx
  • PharmaTher
  • Relmada Therapeutics
  • Seelos Therapeutics
  • Small Pharma
  • UCB

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global NMDA Receptor Antagonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global NMDA Receptor Antagonist Sales Estimates and Forecasts (2021-2032)
  5. 1.3 NMDA Receptor Antagonist Market by Type
  6. 1.3.1 Vaccine
  7. 1.3.2 Monoclonal Antibody
  8. 1.4 Global NMDA Receptor Antagonist Market Size by Type
  9. 1.4.1 Global NMDA Receptor Antagonist Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global NMDA Receptor Antagonist Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global NMDA Receptor Antagonist Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America NMDA Receptor Antagonist Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe NMDA Receptor Antagonist Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific NMDA Receptor Antagonist Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America NMDA Receptor Antagonist Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa NMDA Receptor Antagonist Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 NMDA Receptor Antagonist Industry Trends
  2. 2.2 NMDA Receptor Antagonist Industry Drivers
  3. 2.3 NMDA Receptor Antagonist Industry Opportunities and Challenges
  4. 2.4 NMDA Receptor Antagonist Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by NMDA Receptor Antagonist Revenue (2021-2026)
  2. 3.2 Global Top Players by NMDA Receptor Antagonist Sales (2021-2026)
  3. 3.3 Global Top Players by NMDA Receptor Antagonist Price (2021-2026)
  4. 3.4 Global NMDA Receptor Antagonist Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global NMDA Receptor Antagonist Major Company Production Sites & Headquarters
  6. 3.6 Global NMDA Receptor Antagonist Company, Product Type & Application
  7. 3.7 Global NMDA Receptor Antagonist Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global NMDA Receptor Antagonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 NMDA Receptor Antagonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 NMDA Receptor Antagonist Tier 1, Tier 2, and Tier 3
4 NMDA Receptor Antagonist Regional Status and Outlook
  1. 4.1 Global NMDA Receptor Antagonist Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global NMDA Receptor Antagonist Historic Market Size by Region
  3. 4.2.1 Global NMDA Receptor Antagonist Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global NMDA Receptor Antagonist Sales in Value by Region (2021-2026)
  5. 4.2.3 Global NMDA Receptor Antagonist Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global NMDA Receptor Antagonist Forecasted Market Size by Region
  7. 4.3.1 Global NMDA Receptor Antagonist Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global NMDA Receptor Antagonist Sales in Value by Region (2027-2032)
  9. 4.3.3 Global NMDA Receptor Antagonist Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 NMDA Receptor Antagonist by Application
  1. 5.1 NMDA Receptor Antagonist Market by Application
  2. 5.1.1 Parkinson's Disease
  3. 5.1.2 Alzheimer's Disease
  4. 5.1.3 Others
  5. 5.2 Global NMDA Receptor Antagonist Market Size by Application
  6. 5.2.1 Global NMDA Receptor Antagonist Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global NMDA Receptor Antagonist Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global NMDA Receptor Antagonist Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America NMDA Receptor Antagonist Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe NMDA Receptor Antagonist Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific NMDA Receptor Antagonist Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America NMDA Receptor Antagonist Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa NMDA Receptor Antagonist Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Algernon Pharmaceuticals
  2. 6.1.1 Algernon Pharmaceuticals Company Information
  3. 6.1.2 Algernon Pharmaceuticals Business Overview
  4. 6.1.3 Algernon Pharmaceuticals NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Algernon Pharmaceuticals NMDA Receptor Antagonist Product Portfolio
  6. 6.1.5 Algernon Pharmaceuticals Recent Developments
  7. 6.2 ATAI Life Sciences
  8. 6.2.1 ATAI Life Sciences Company Information
  9. 6.2.2 ATAI Life Sciences Business Overview
  10. 6.2.3 ATAI Life Sciences NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 ATAI Life Sciences NMDA Receptor Antagonist Product Portfolio
  12. 6.2.5 ATAI Life Sciences Recent Developments
  13. 6.3 Avanir Pharmaceuticals
  14. 6.3.1 Avanir Pharmaceuticals Company Information
  15. 6.3.2 Avanir Pharmaceuticals Business Overview
  16. 6.3.3 Avanir Pharmaceuticals NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Avanir Pharmaceuticals NMDA Receptor Antagonist Product Portfolio
  18. 6.3.5 Avanir Pharmaceuticals Recent Developments
  19. 6.4 Axsome Therapeutics
  20. 6.4.1 Axsome Therapeutics Company Information
  21. 6.4.2 Axsome Therapeutics Business Overview
  22. 6.4.3 Axsome Therapeutics NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Axsome Therapeutics NMDA Receptor Antagonist Product Portfolio
  24. 6.4.5 Axsome Therapeutics Recent Developments
  25. 6.5 Bexson Biomedical
  26. 6.5.1 Bexson Biomedical Company Information
  27. 6.5.2 Bexson Biomedical Business Overview
  28. 6.5.3 Bexson Biomedical NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Bexson Biomedical NMDA Receptor Antagonist Product Portfolio
  30. 6.5.5 Bexson Biomedical Recent Developments
  31. 6.6 Cessatech
  32. 6.6.1 Cessatech Company Information
  33. 6.6.2 Cessatech Business Overview
  34. 6.6.3 Cessatech NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Cessatech NMDA Receptor Antagonist Product Portfolio
  36. 6.6.5 Cessatech Recent Developments
  37. 6.7 DemeRx
  38. 6.7.1 DemeRx Company Information
  39. 6.7.2 DemeRx Business Overview
  40. 6.7.3 DemeRx NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 DemeRx NMDA Receptor Antagonist Product Portfolio
  42. 6.7.5 DemeRx Recent Developments
  43. 6.8 PharmaTher
  44. 6.8.1 PharmaTher Company Information
  45. 6.8.2 PharmaTher Business Overview
  46. 6.8.3 PharmaTher NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 PharmaTher NMDA Receptor Antagonist Product Portfolio
  48. 6.8.5 PharmaTher Recent Developments
  49. 6.9 Relmada Therapeutics
  50. 6.9.1 Relmada Therapeutics Company Information
  51. 6.9.2 Relmada Therapeutics Business Overview
  52. 6.9.3 Relmada Therapeutics NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Relmada Therapeutics NMDA Receptor Antagonist Product Portfolio
  54. 6.9.5 Relmada Therapeutics Recent Developments
  55. 6.10 Seelos Therapeutics
  56. 6.10.1 Seelos Therapeutics Company Information
  57. 6.10.2 Seelos Therapeutics Business Overview
  58. 6.10.3 Seelos Therapeutics NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Seelos Therapeutics NMDA Receptor Antagonist Product Portfolio
  60. 6.10.5 Seelos Therapeutics Recent Developments
  61. 6.11 Small Pharma
  62. 6.11.1 Small Pharma Company Information
  63. 6.11.2 Small Pharma Business Overview
  64. 6.11.3 Small Pharma NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Small Pharma NMDA Receptor Antagonist Product Portfolio
  66. 6.11.5 Small Pharma Recent Developments
  67. 6.12 UCB
  68. 6.12.1 UCB Company Information
  69. 6.12.2 UCB Business Overview
  70. 6.12.3 UCB NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 UCB NMDA Receptor Antagonist Product Portfolio
  72. 6.12.5 UCB Recent Developments
7 North America by Country
  1. 7.1 North America NMDA Receptor Antagonist Sales by Country
  2. 7.1.1 North America NMDA Receptor Antagonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America NMDA Receptor Antagonist Sales by Country (2021-2026)
  4. 7.1.3 North America NMDA Receptor Antagonist Sales Forecast by Country (2027-2032)
  5. 7.2 North America NMDA Receptor Antagonist Market Size by Country
  6. 7.2.1 North America NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America NMDA Receptor Antagonist Market Size by Country (2021-2026)
  8. 7.2.3 North America NMDA Receptor Antagonist Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe NMDA Receptor Antagonist Sales by Country
  2. 8.1.1 Europe NMDA Receptor Antagonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe NMDA Receptor Antagonist Sales by Country (2021-2026)
  4. 8.1.3 Europe NMDA Receptor Antagonist Sales Forecast by Country (2027-2032)
  5. 8.2 Europe NMDA Receptor Antagonist Market Size by Country
  6. 8.2.1 Europe NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe NMDA Receptor Antagonist Market Size by Country (2021-2026)
  8. 8.2.3 Europe NMDA Receptor Antagonist Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific NMDA Receptor Antagonist Sales by Country
  2. 9.1.1 Asia-Pacific NMDA Receptor Antagonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific NMDA Receptor Antagonist Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific NMDA Receptor Antagonist Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific NMDA Receptor Antagonist Market Size by Country
  6. 9.2.1 Asia-Pacific NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific NMDA Receptor Antagonist Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific NMDA Receptor Antagonist Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America NMDA Receptor Antagonist Sales by Country
  2. 10.1.1 South America NMDA Receptor Antagonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America NMDA Receptor Antagonist Sales by Country (2021-2026)
  4. 10.1.3 South America NMDA Receptor Antagonist Sales Forecast by Country (2027-2032)
  5. 10.2 South America NMDA Receptor Antagonist Market Size by Country
  6. 10.2.1 South America NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America NMDA Receptor Antagonist Market Size by Country (2021-2026)
  8. 10.2.3 South America NMDA Receptor Antagonist Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa NMDA Receptor Antagonist Sales by Country
  2. 11.1.1 Middle East and Africa NMDA Receptor Antagonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa NMDA Receptor Antagonist Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa NMDA Receptor Antagonist Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa NMDA Receptor Antagonist Market Size by Country
  6. 11.2.1 Middle East and Africa NMDA Receptor Antagonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa NMDA Receptor Antagonist Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa NMDA Receptor Antagonist Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 NMDA Receptor Antagonist Value Chain Analysis
  2. 12.1.1 NMDA Receptor Antagonist Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 NMDA Receptor Antagonist Production Mode & Process
  7. 12.2 NMDA Receptor Antagonist Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 NMDA Receptor Antagonist Distributors
  10. 12.2.3 NMDA Receptor Antagonist Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst